US catches up to rest of world with first new FDA-approved sunscreen in decades
US catches up to rest of world with first new FDA-approved sunscreen in decades
US catches up to rest of world - The Food and Drug Administration (FDA) has made a significant move in the skincare industry by approving the first new sunscreen filter in over two decades. This development has generated enthusiasm across the sector, particularly as the ingredient, bemotrizinol, is already well-established in global markets but remains unfamiliar to U.S. consumers.
A Game-Changer for Sunscreen Formulation
On Tuesday, the FDA extended its list of approved sunscreen active ingredients by adding bemotrizinol, marketed as PARSOL® Shield. This decision marks the end of a 27-year gap in introducing novel UV protection components to the American market. The approval process had been anticipated since December, when former FDA commissioner Marty Makary hinted that regulatory delays in this area were beginning to ease.
The Swiss-Dutch corporation DSM-Firmenich submitted the application for bemotrizinol’s approval. The company has secured exclusive rights to market the ingredient for the first 18 months post-approval, positioning itself as the sole supplier during this period. Industry players have already expressed interest in integrating the new filter into their formulations, suggesting a potential shift in product offerings.
The Approval Process and Industry Impact
Bemotrizinol belongs to the chemical filters, also known as organic filters, which function differently from mineral-based alternatives like zinc oxide or titanium dioxide. Unlike many existing organic filters, it provides broad-spectrum protection, covering both UVA and UVC radiation. This dual capability makes it a promising addition to the sunscreen landscape, offering more comprehensive sun protection.
The American Academy of Dermatology praised the approval, highlighting its importance in expanding consumer choices for UV protection. In a statement, the organization emphasized that the decision reflects years of advocacy to enhance the effectiveness of sunscreens against harmful rays. This endorsement underscores the potential of bemotrizinol to address long-standing concerns about sun safety.
Comparing UV Protection Categories
UV filters are typically divided into two groups: mineral-based and chemical-based. Mineral sunscreens rely on physical barriers to reflect UV radiation, while chemical filters absorb it. The latter category, though effective, often faces criticism for its texture and stability under sunlight. For example, avobenzone, the only other broad-spectrum chemical filter approved in the U.S., is known to degrade when exposed to UV light.
Bemotrizinol stands out for its stability and user-friendly properties. Gabriella Baki, a cosmetic science expert at Toledo University, noted that the ingredient’s attributes make it a compelling option for manufacturers. She explained that its non-absorbent nature reduces the risk of penetration into the bloodstream, a factor that has historically influenced consumer preferences. This characteristic could ease concerns about long-term safety, encouraging broader adoption.
Advantages Over Traditional Organic Filters
Baki also highlighted the aesthetic benefits of bemotrizinol. Unlike many chemical filters, which leave an oily residue, it offers a more pleasant texture that aligns with modern consumer expectations. This feature addresses a common complaint about traditional sunscreens, which are often perceived as heavy or uncomfortable to apply.
Furthermore, the FDA has granted bemotrizinol the status of Generally Recognized As Safe and Effective (GRASE), a critical endorsement for product development. Other chemical filters, such as octocrylene, homosalate, and oxybenzone, are permitted in the U.S. but lack GRASE recognition. This distinction elevates bemotrizinol’s credibility and positions it as a key innovation in the field.
Why the Delay? FDA’s Regulatory Hurdles
The FDA’s prolonged hesitation in approving new sunscreen filters has raised questions about its regulatory efficiency. Jessica O’Connell, a legal expert at Covington & Burling, noted that the agency historically viewed the process as resource-intensive. She explained that the Time and Extent Approach (TEA) was used to streamline the approval of over-the-counter drugs, including sunscreens. However, this method limited the depth of evaluation for new ingredients.
“This particular application remained in limbo for years,” O’Connell stated. “The FDA seemed to believe that the data provided wasn’t sufficient for a full assessment, which delayed the process.” The TEA pathway allowed for quicker approvals but at the cost of thorough scrutiny. This approach may have contributed to the slow pace of innovation in the U.S. sunscreen market.
Legislative Efforts and Future Prospects
Recognizing the need for reform, Congress introduced the Sunscreen Innovation Act in 2014. The legislation aimed to create a more efficient pathway for evaluating new ingredients. However, its implementation did not immediately resolve the backlog, leaving the FDA to rely on the TEA process for much of the time.
Despite the act’s intentions, the approval of bemotrizinol suggests a turning point. This achievement may signal a broader shift toward modernizing the FDA’s approach to sunscreen regulation. Industry experts anticipate that the new ingredient could inspire further advancements, potentially leading to more options for consumers who prioritize both efficacy and comfort.
As the skincare industry evolves, the integration of bemotrizinol into U.S. products could redefine sun protection standards. Its approval not only fills a gap in the market but also addresses consumer demands for better-performing, more aesthetically pleasing sunscreens. With the FDA’s recognition, the ingredient is now poised to make an impact, offering a solution that balances protection, stability, and user experience.
Global Standards and Domestic Progress
While the FDA is respected worldwide for its rigorous drug approval processes, the lengthy approval of bemotrizinol highlights the challenges of maintaining global competitiveness. The delay raises questions about the agency’s ability to adapt to changing scientific and consumer needs. However, the recent decision demonstrates a willingness to update its framework, potentially setting a precedent for future approvals.
Experts like O’Connell suggest that the FDA’s approval of bemotrizinol reflects a renewed commitment to innovation. The ingredient’s GRASE status and performance profile could pave the way for additional chemical filters to gain regulatory clearance. This shift may ultimately lead to a more diverse range of sunscreens, better tailored to the preferences of modern users.
As the sunscreen market expands, bemotrizinol’s introduction is a step toward aligning U.S. standards with those of other countries. Its approval not only benefits consumers but also reinforces the FDA’s role as a leader in product safety and efficacy. With this milestone, the agency has taken a significant stride toward updating its approach to skincare, ensuring that American consumers have access to the latest advancements in UV protection technology.